Liver Cancer

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

By

Previous studies have demonstrated tivantinib prolonged progression-free survival and overall survival in hepatocellular carcinoma.

Radioembolization Shows Similar OS, Improved Toxicity vs Sorafenib in Hepatocellular Carcinoma

Radioembolization Shows Similar OS, Improved Toxicity vs Sorafenib in Hepatocellular Carcinoma

By

Patients were enrolled regardless of portal vein thrombosis status and were unable to tolerate other curative therapies.

Individualized Radiotherapy Effective in Liver Cancer

Individualized Radiotherapy Effective in Liver Cancer

By

The 1-year control rate was 99%, the 2-year control rate was 95%, and the median time to progression was 9 months.

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

By

The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.

FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

By

Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.

RETREAT Score Highly Predictive of HCC Recurrence Risk After Liver Transplantation

RETREAT Score Highly Predictive of HCC Recurrence Risk After Liver Transplantation

By

The Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score was highly predictive of hepatocellular carcinoma (HCC) recurrence risk.

Polycystic Kidney Disease Correlated With Risk of Cancer

Polycystic Kidney Disease Correlated With Risk of Cancer

By

Polycystic kidney disease (PKD) may increase one's risk of developing cancer of the liver, colon, and kidney.

Regorafenib Improves Survival in Unresectable Liver Cancer

Regorafenib Improves Survival in Unresectable Liver Cancer

By

The kinase inhibitor regorafenib conferred improved overall survival in patients with unresectable hepatocellular carcinoma (HCC).

Sartans May Improve Survival, Time to Recurrence in Liver Cancer

Sartans May Improve Survival, Time to Recurrence in Liver Cancer

For patients with hepatocellular carcinoma, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved survival.

Sorafenib Not Effective After Resection, Ablation for Hepatocellular Carcinoma

Sorafenib Not Effective After Resection, Ablation for Hepatocellular Carcinoma

By

Treatment with sorafenib is not effective in the adjuvant setting for hepatocellular carcinoma following resection or ablation.

Three Alcoholic Drinks Per Day Raises Liver Cancer Risk

Three Alcoholic Drinks Per Day Raises Liver Cancer Risk

People who have three or more alcoholic drinks per day could be raising their odds for liver cancer.

American Patients Living Longer After Cancer, But Disparities Remain

American Patients Living Longer After Cancer, But Disparities Remain

Survival rates are improving for many people with cancers of the breast, prostate, lung, liver, and colon or rectum.

Addition of Erlotinib to Sorafenib Does Not Improve Survival in Advanced Liver Cancer

Addition of Erlotinib to Sorafenib Does Not Improve Survival in Advanced Liver Cancer

Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.

A New Approach to Assessing Liver Function in Hepatocellular Carcinoma

A New Approach to Assessing Liver Function in Hepatocellular Carcinoma

By

By analyzing data from international databases, researchers develop an alternative to the Child-Pugh system.

Safety, Efficacy of Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups

Safety, Efficacy of Sorafenib Treatment for Hepatocellular Carcinoma Among Age Groups

Safety and efficacy of sorafenib, the standard of care for advanced hepatocellular carcinoma, in older patients, evaluated.

Biomarker May Predict Response to Sorafenib in Patients with Liver Cancer

Biomarker May Predict Response to Sorafenib in Patients with Liver Cancer

Patients with liver cancer whose tumors cells have less differentiated mesenchymal phenotype and CD44 are less likely to respond to sorafenib.

Obesity Speeds Aging of Liver, Linked to Cancer

Obesity Speeds Aging of Liver, Linked to Cancer

Heavier people might be more prone to liver cancer, insulin problems.

NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs Survival

NANETS: Radical Resection of Pancreatic Neuroendocrine Tumors with Liver Mets Often Prolongs Survival

By

Poorly differentiated pancreatic neuroendocrine carcinoma (PNEC) grade 3 tumors demonstrate lower survival after radical resection of PNETs.

For Hepatocellular Carcinoma, Protein May Trigger Cancer Cell Death

For Hepatocellular Carcinoma, Protein May Trigger Cancer Cell Death

Researchers have discovered that a protein called apoptosis inhibitor of macrophage (AIM) prevents tumor development in liver cells.

Sorafenib Plus Selective Internal Radiation Therapy (SIRT) Improves Survival for Patients with Liver Cancer

Sorafenib Plus Selective Internal Radiation Therapy (SIRT) Improves Survival for Patients with Liver Cancer

Patients with advanced hepatocellular carcinoma may benefit from combined therapy of sorafenib and selective internal radiation therapy.

Everolimus Didn't Improve Survival in Advanced HCC

Everolimus Didn't Improve Survival in Advanced HCC

Researchers found no survival difference found between patients receiving everolimus or placebo.

Benefits of HCC Screening Remain Unclear

Benefits of HCC Screening Remain Unclear

The benefits of hepatocellular carcinoma screening are unclear in patients with chronic liver disease.

Vitamin D May Lower Liver Cancer Risk

Vitamin D May Lower Liver Cancer Risk

A new study in Western Europeans shows that vitamin D lowers the risk of developing hepatocellular carcinoma.

Antivirals May Protect HBV Patients from Liver Cancer

Antivirals May Protect HBV Patients from Liver Cancer

Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma.

AFP Detects Liver Cancer in Patients Without HCV

AFP Detects Liver Cancer in Patients Without HCV

Measurement of α-fetoprotein detects hepatocellular carcinoma most accurately in patients without hepatitis C virus infection.

Updated Results Announced for ThermoDox Use for HCC

Updated Results Announced for ThermoDox Use for HCC

Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC).

Lipiodol Earns FDA Approval for Tumor Imaging in HCC

Lipiodol Earns FDA Approval for Tumor Imaging in HCC

By

The FDA has approved Guerbet's Lipiodol (ethiozed oil) injection for imaging of hepatocellular carcinoma tumors

Drinking More Coffee May Lower Liver Cancer Risk

Drinking More Coffee May Lower Liver Cancer Risk

Increased coffee consumption may reduce hepatocellular carcinoma risk across ethnicities, according to a study presented at the AACR Annual Meeting.

Coffee Consumption Linked to 40% Reduced Risk of Liver Cancer

Coffee Consumption Linked to 40% Reduced Risk of Liver Cancer

Coffee consumption is associated with a 40% reduction in the risk of liver cancer.

Anti-CLTA4 Immunotherapy Achieves Antitumor Effects in Small Study of Hepatitis C-Related Hepatocellular Carcinoma

Anti-CLTA4 Immunotherapy Achieves Antitumor Effects in Small Study of Hepatitis C-Related Hepatocellular Carcinoma

By

Immunotherapy targeting the CLTA4 protein in HCV-related HCC demonstrated modest extended survival in a disease that has a high mortality rate.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs